
usd jan pm et
summari johnson johnson global leader pharmaceut medic devic consum
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
sale rose modestli yoy driven
market growth yoy
sale offset
lacklust growth consum yoy
sale yoy declin
medic devic sale due larg
neg one-off japan vision busi
thank sustain double-digit sale growth
key drug -- stelara auto-immun
darzalex myeloma continu
off-set neg impact biosimilar
gener competit medic devic
report organ growth yoy
modest increas sub-seg
offset declin surgeri
sale result intens
competit surgeri past
driven beauti product yoy
sale over-the-counter medicin yoy
sale offset declin babi care
jnj organ growth guidanc
achiev view
market growth pharma consum
beauti over-the-counter
lift target
januari rais view buy hold
reflect outlook share gain potenti
think litig risk price
express confid favor
resolut settlement offer opioid
alleg view also like
moreov close highest
level free cash flow date
ampl liquid litig relat
cash outflow view compar peer
solid balanc sheet low
debt net debt/ebitda
think pharma sale
promis long-term growth prospect
segment thank strong prospect
exist key drug stelara imbruvica
darzalex robust drug pipelin
novel drug launch expect end
view
risk view includ pipelin failur
increas pressur drug price neg
headlin litig matter well
advers legal judgment target
ep estim line current
forward price-to-earnings compar
pharma peer averag
risk assess reflect benefit
product larg immun econom cycl
earn diversifi across mani product
categori hold competit advantag
health care provid custom result divers
product mix view well larg scale
strength balanc unpredict natur
 pipelin drug patent challeng well
potenti advers legal rule health care
product develop rise scrutini drug cost
 also pose threat new regul drug
price patent protect
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview johnson johnson largest health care product compani world
revenu span pharmaceut medic devic consum product
segment sale develop market wide rang synthet
biolog drug import therapeut area inflamm
immunolog drug total revenu treat autoimmun diseas like crohn diseas
psoriasi arthriti oncolog drug treat tumor form cancer neurosci
drug disord like depress schizophrenia cardiovascular drug treat
high blood pressur prevent blood clot stroke
pharmaceut product complex difficult develop often consum sever year billion
invest dollar found ineffect late-stag human trial fail pass regulatori
approv hurdl occur take larg write-down in-process asset
exampl produc charg compani incom statement despit failur risk
spend heavili spend
goe toward acquir compani promis pipelin drug frequent reinvest new drug
need keep pipelin full potenti market drug eventu replac exist drug
time lose market share compet treatment becom obsolet due new one
uncertainti involv develop market success pharmaceut largest risk
earn view billion invest dollar risk never produc
profit drug compet version drug success patent challeng court
competitor cut short success drug profit lifespan one recent exampl best-sel
drug remicad sale vs biolog drug began lose sale due
biosimilar akin gener biolog drug approv approv biosimilar
remicad sale fell biosimilar enter market
anoth top-sel drug zytiga sale held patent initi valid
lengthi court battl sever gener competitor right market gener form zytiga
begin late accordingli zytiga sale fell
medic devic segment sale sell wide rang health care product includ
wound care surgic instrument implant hip knee replac spinal implant like
pharmaceut medic devic segment also depend invest develop innov
consum segment sale sell wide varieti person care product one might find
groceri store retail pharmaci includ over-the-count medicin adult skin hair care
product babi care oral care first aid women health nutrit supplement consum
segment includ major brand-nam like band-aid listerin johnson babi care line neutrogena
aveeno skin hair care product mani well-known over-the-count medicin like tylenol pepcid
sudaf
corpor strategi despit industri lead scale highli innov view seek
maintain leadership posit aggress fund new product develop spend
total repres sale major devot drug develop januari
late-stag clinic drug trial underway fda file review process mani
trial expand treatment indic exist drug also expect compani launch
least seven novel drug end
although intern growth key object also pursu strateg acquisit spend
four deal largest acquisit jnj histori
acquir billion retain actelion market drug mainli treat hypertens
late stage compound divest discoveri stage oper spin-off
legal/regulatori issu face alleg regard role opioid crisi asbesto
find babi talc powder variou lawsuit although outcom variou lawsuit remain
unclear think favor outcom like certain near-term legal issu earn call
express confid favor resolut settlement offer opioid alleg
moreov decemb articl journal american medic associ studi point
link talc cancer strengthen jnj hand issu
financi trend total revenu grew equat compound
annual growth rate compound-annual-growth-rate period adjust ep grew
compound-annual-growth-rate grown ep faster sale mainli margin improv
revenu mix shift toward higher margin pharmaceut late adjust oper margin
improv around also return materi capit sharehold
repurchas dividend combin total
consist share repurchas polici buy back share deem stock
under-valued recent complet share repurchas program januari
new share repurchas author ep guidanc per share assum
share repurchas
stabl dividend payer thank solid balanc sheet view distribut
dividend increas quarterli dividend yoy expect dividend appreci
continu line previou year howev note current dividend yield
stand slightli lower compar peer offer dividend yield averag
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
recent slowdown novel drug approv
potenti new industri price regul
neg partial off-set
upcom period low patent expir
also expect major gener maker continu
struggl due lower-cost emerg
follow banner year novel drug approv
fda signific
slowdown occur think
weigh drug maker revenu growth next
year novel brand drug enter market
gener competit often rival brand
either provid signific boost
revenu firm market
total number fda novel drug
approv fell versu
expect mean less revenu boost
major brand drug maker year ahead
estim sub-industri total
 spend pace
yoy declin septemb like
reflect effort maintain margin
sluggish revenu growth year ahead
addit fewer new brand enter
risk new price rule view
accord studi wall street
govern health system develop
countri like england norway canada
often pay less major drug
medicar kaiser famili foundat
poll indic american feel
drug cost unreason believ
dynam rais pressur drug maker
curtail usual price hike
politician enact polici lower
drug cost voter accordingli sever new
propos lower drug price emerg
side isl recent month
includ bill hous democrat
would allow medicar directli negoti
price drug maker senat
maximum medicar drug plan shift
cost burden drug maker
unclear new propos
enough support becom law see
polit parti increas focu
control drug cost signific risk
weigh outlook
balanc neg factor face
brand drug maker upcom period
low patent expir typic
biggest revenu headwind loss patent
protect open door gener
biosimilar competit base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
gener drug firm neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
saw occur last year establish firm
like israel-bas teva saw sale
declin year-to-d thru sale
india-bas aurobindo sun pharma
grew yoy think due
rise broader composit
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep hold opinion share johnson johnson
keep target ep estim line
histor forward price-to-earnings averag ep estim
maintain ep vs consensu
mark slow growth across segment organ revenu growth
yoy full-year pharmaceut revenu
experienc sharpest slowdown yoy growth vs full-year
segment saw oncolog total revenu grow
impress yoy also saw declin remicad
autoimmun due biosimlar entri xarelto stroke market share loss
stroke drug eliqui bottom line non-gaap ep grew yoy
benefit one-tim non-oper gain sale exclud gain
estim adjust pre-tax incom per share grew yoy remain neutral
share expect earn growth outpac peer /colin scarola
pm et cfra keep hold opinion share johnson johnson
rais target price ep
estim -- in-lin histor forward price-to-earnings averag keep
ep estim rais ep
vs consensu revenu flat yoy
sale growth yoy off-set declin yoy medic
devic consum respect immunolog treatment revenu
oncolog drug show strong sale growth yoy
respect despit flat revenu quarter adjust pre-tax incom per
share declin yoy driven ramp spend grew
yoy think invest heavili futur growth wise
sever key drug face gener biosimilar competit expect
free cash flow return capit remain strong think share
current near fair valu /colin scarola
analyst research note compani news
pm et cfra lift opinion share johnson johnson buy
hold lift target
ep estim line current ntm forward price-to-earnings reflect view
share gain potenti think litig risk price
lower ep estim stay within jnj ep
guidanc expect small fx impact start estim
ep vs consensu sale rose modestli
yoy driven market growth yoy
sale offset lacklust growth consum yoy sale
yoy declin medic devic sale due larg
neg one-off japan vision busi sale key drug stelara
imbruvica darzalex continu off-set neg impact biosimilar
gener competit provid organ growth guidanc
achiev view solid above-market growth pharma
consum beauti over-the-counter /sel hardi
pm et cfra keep hold opinion share johnson johnson
maintain ep estim target price today
announc recal babi powder recent fda test found
asbesto contamin litig babi powder asbestos-rel
claim sever year least plaintiff june
sever neg verdict alreadi total nearli billion
appeal rule think fda discoveri help plaintiff
on-going case view prove increasingli difficult
claim product never contain asbesto respect regul like
fda found otherwis litig though signific
new find ramif ultim legal liabil remain
highli uncertain howev even near-term impact
earn balanc sheet see legal uncertainti limit upsid
share investor sentiment like subdu clariti arriv
et cfra see investor sentiment improv defend
nation opioid case key bellweth trial opioid
epidem schedul begin monday intent presid judg
bring side comprehens settlement resolv relat
case nationwid trial approach see flurri report
settlement negoti includ news week big drug
distributor propos cap total liabil pay
year produc teva offer settlement worth
respect earli know coalit
state attorney lead negoti behalf plaintiff stand
offer see defend willing settl posit news opioid
litig uncertainti gener cost defend market valu via
neg sentiment like cost settl view move
toward settlement even costli one defend see share rise
uncertainti allevi /colin scarola
et cfra keep hold opinion share johnson johnson
drop target ep estim line
histor forward price-to-earnings averag lift ep estim
keep ep vs beat
consensu return growth lift top line yoy
growth sale drug sale bolster
stelara auto-immun total sale yoy imbruvica
leukemia darzalex myeloma brand
impress off-set biosimilar/gener driven drop remicad
auto-immun zytiga prostat cancer medic devic
consum kept pace though year-to-d sale
yoy come buyback remain neutral
expect faster organ growth sever peer see litig risk
weigh sentiment /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
